3-methoxy-4-(pyrrolidin-1-ylmethyl)phenol | 917828-11-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-methoxy-4-(pyrrolidin-1-ylmethyl)phenol
• CAS: 917828-11-6
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD24390743
• 分子量: 207.272
• InChiKey: PMZVSEGOKUSCOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  四氢吡咯 、 4-羟基-2-甲氧基苯甲醛 在 三乙酰氧基硼氢化钠 、 sodium hydroxide 、 水 、 盐酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 3-methoxy-4-(pyrrolidin-1-ylmethyl)phenol
  参考文献：
  名称：

  WO2006/136924

  摘要：

  公开号：

文献信息

• Histamine-3 receptor antagonists
  申请人：Pfizer Inc.

  公开号：US07812040B2

  公开（公告）日：2010-10-12

  This invention is directed to a compound of the formula Ia or Ib, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及公式Ia或Ib的化合物，如本文所定义，或其药学上可接受的盐；含有公式I化合物的制药组合物；一种治疗通过拮抗组胺H3受体可治疗的紊乱或疾病的方法，该方法包括向需要该治疗的哺乳动物给予上述的公式I化合物；以及一种治疗从以下组中选择的紊乱或疾病的方法，该组包括抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷/多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏引起的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低运动和酸性分泌的方法，该方法包括向需要该治疗的哺乳动物给予上述的公式I化合物。
• HISTAMINE-3 RECEPTOR ANTAGONISTS
  申请人：Wager Travis T.

  公开号：US20090131433A1

  公开（公告）日：2009-05-21

  This invention is directed to a compound of the formula Ia or Ib, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及公式Ia或Ib的化合物，如本文所定义，或其药学上可接受的盐; 包含公式I化合物的制药组合物; 一种治疗通过拮抗组胺H3受体可以治疗的疾病或症状的方法，该方法包括向需要此类治疗的哺乳动物注射上述的公式I化合物; 以及一种治疗选择自抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏引起的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低运动性和酸性分泌的方法，该方法包括向需要此类治疗的哺乳动物注射上述的公式I化合物。
• US7812040B2
  申请人：——

  公开号：US7812040B2

  公开（公告）日：2010-10-12
• [EN] HISTAMINE-3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR 3 DE L'HISTAMINE
  申请人：PFIZER PROD INC

  公开号：WO2006136924A1

  公开（公告）日：2006-12-28

  [EN] This invention is directed to a compound of the formula Ia or Ib. as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy- induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the Gl tract, hyper and hypo motility and acidic secretion of the gastro- intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.
  [FR] L'invention concerne un composé représenté par la formule Ia ou Ib, définie dans le descriptif, ou un sel pharmaceutiquement acceptable de celui ci, une compositions pharmaceutique contenant un composé représenté par la formule I, une méthode permettant le traitement d'un trouble ou d'une affection susceptible d'être traitée par antagonisation des récepteurs H3 de l'histamine, cette méthode consistant à administrer à un mammifère nécessitant un tel traitement un composé défini par la formule I ci-dessus, et une méthode permettant de traitement un trouble ou une affection choisis dans le groupe constitué par la dépression, les troubles de l'humeur, la schizophrénie, les troubles anxieux, la maladies d'Alzheimer, les troubles de déficit d'attention (TDA), les déficits de l'attention avec hyperactivité (TDAH), les troubles psychotiques, les troubles du sommeil, l'obésité, les vertiges, l'épilepsie, les maux des transports, les maladies respiratoires, les allergies, les réactions des voies respiratoires d'origine allergique, les rhinites allergiques, la congestion nasale, les congestions allergiques, les congestions, l'hypotension, les maladies cardiovasculaires, les maladies du tractus GI, l'hyper et l'hypomotilité, et les sécrétions acides du tractus gastro-intestinal, cette méthode consistant à administrer à un mammifère nécessitant un tel traitement un composé représenté par la formule I ci-dessus.
• WO2006/136924
  申请人：——

  公开号：——

  公开（公告）日：——